Meet Adaeze Nwosu Iheme, M.D.
Adaeze Nwosu Iheme, M.D.
Department of General Oncology, Division of Cancer Medicine
About Dr. Adaeze Nwosu Iheme
Dr. Adaeze Iheme is a breast medical oncologist at MD Anderson Cancer Center, she completed her fellowship training in Hematology and Oncology at the University of Florida in Gainesville and her internal medicine residency training at Beth Israel Hospital in New Jersey. She is very passionate about caring for her patients with breast cancer and treats every patient like her family member. She is particularly interested in breast cancer genetics and educating the public on their risks of breast and other cancers. Dr Iheme is board certified in both oncology and hematology. She is a member of the American Society of Clinical Oncology, has co-authored peer reviewed publications and given oral and poster presentations at the national conferences.
Present Title & Affiliation
Primary Appointment
Assistant Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor (Joint appointment), Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor (Joint Appointment), Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2013 | St. George's University School of Medicine, West Indies, GD, MD |
| 2008 | IMO State University, IMO, NG, MD |
Postgraduate Training
| 2016-2019 | Clinical Fellowship, Hematology/Oncology, University of Florida, Gainesville, Florida |
| 2013-2016 | Clinical Residency, Internal Medicine, Newark Beth Israel Medical Center, Newark, New Jersey |
Licenses & Certifications
| 2024 | Arizona Board of Medical Examiners |
| 2024 | Washington State Department of Health |
| 2024 | Tennessee Board of Medical Examiners |
| 2024 | Georgia Composite Medical Board |
| 2023 | Florida Board of Medicine |
| 2023 | Mississippi State Board of Medical Licensure |
| 2023 | Louisiana State Board of Medical Examiners |
| 2023 | Oklahoma State Board of Medical Licensure |
| 2022 | Alabama Board of Medical Examiners |
| 2019 | American Board of Internal Medicine-Hematology |
| 2019 | DEA |
| 2018 | Texas Medical License |
| 2016 | American Board of Internal Medicine |
Experience & Service
Other Professional Positions
Consultant, Victoria Hematology-Oncology Associates, Victoria, TX, 2019 - Present
Extramural Institutional Committee Activities
Member, Blood Transfusion Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Scientific Review Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Honors & Awards
| 2017 - 2018 | ASCO Educational Book Expert Panel, ASCO |
| 2017 | Travel Award, Florida Association of Clinical Oncology |
| 2015 - 2016 | RWJ Barnabas Health Chief Resident, Beth Israel Medical Center |
| 2015 - 2016 | Top Resident Representative, Resident Cultural Forum |
| 2015 | American College of Physician's Young Achiever's Award, American College of Physicians |
| 2008 | Gold Stethoscope Award, WIMS Nigeria |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2023. Patient Education and Empowerment Webinar on Understanding HER2+ and Early-Stage Breast Cancer. Invited. National African American Breast Cancer Survivorship Organization. Houston, TX, US.
- 2023. Breast Cancer Screening and Current Approaches to Treatment. Invited. Houston, Texas, US.
- 2023. Rice University Education Panel on Breast Cancer, Genetics, Gender Equity (Speaker/Panelist). Invited. Houston, TX, US.
- 2023. Surviving Breast Cancer. Invited. Houston, Texas, US.
- 2022. Question and Answer Session on Breast Cancer. Invited. Houston, Texas, US.
- 2022. Power of Breast Cancer Survivorship. Invited. Houston, Texas, US.
Regional Presentations
- 2023. The Efficacy and Safety of Tinengotinib in Patients with Advanced or Metastatic HR+/HER2-breast Cancer or TNBC. Invited. San Antonio Breast Cancer Symposium.
- 2022. Black Women Speak Symposium on Dismantling Barriers in Breast Cancer, Increasing Participation of Minorities in Clinical Trials. Invited. San Antonio Breast Cancer Symposium.
International Presentations
- 2024. Overview of Treatment for Breast Cancer. Invited. Guangzhou, CN.
Selected Publications
Peer-Reviewed Articles
- Skelton WP, Dibenedetto SW, Pang SS, Pan K, Barish JL, Nwosu-Iheme A, Dang L. A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer. Cureus 12(1):e6806, 2020. e-Pub 2020. PMID: 32140364.
- Nwosu-Iheme A, Ghanem S, Patel A, Zhuang Y, Seifert R, Murthy H. A Rare Presentation of Hemophagocytic Lymphohistiocytosis in a Patient with Untreated Chronic Lymphocytic Leukemia: A case report and review of the literature. Herbert Open Access Journals 6(2):1-5, 2018. e-Pub 2018.
- Patel A, Ghanem S, Nwosu-Iheme A, Fletcher B. Idiopathic Pulmonary Vein Thrombosis – A presentation of two case reports and review of the current literature. Symbiosis online publishing 2:1-6, 2017. e-Pub 2017.
- Vijaykumar, Baran D, Nwosu-Iheme A. Successful Use of Extracorporeal Membrane Oxygenation for Silicone Embolism Syndrome and Pulmonary Hemorrhage. Chest Journal, 2016. e-Pub 2016.
- Orsini J, Nwosu-Iheme A, Medavaram S, Cohen AJ. Pituitary Metastasis from Breast Cancer Presenting as SIADH. Journal Of Endocrinology & Metabolism 5(4):256-260, 2015. e-Pub 2015.
- Shah S, Nwosu-Iheme A, Cohen AJ. Impact of Hydroxyurea on Sickle Cell Patients Managed in a Community Medical Center. Ash Publications 126(23):3411, 2015. e-Pub 2015.
Editorials
- Nwosu-Iheme A, Unnikrishnan A. Selecting Patients for CDK4/6 Inhibitors in Metastatic Breast Cancer. ASCO Daily Post.
Abstracts
- Mouabbi JA, Raghavendra A, Pasyar S, Roland B, Mukhtar R, Moscol G, Wright MD, Bisen AK, Iheme AN, Barcenas CH, Valero V, Nasrazadani A, Lim B, Ramirez DL, Hassan A, Kuerer H, Adesoye T, Paula P, Meric-Bernstam F, Giordano SH, Litton JK, Layman RM. Validation of the CTS5 as a predictor of late distant recurrence (DR) for HR+ HER2-negative Invasive Lobular Carcinoma (ILC). Clin Cancer Res 32(4 Supplement), 2026. e-Pub 2026.
- Wright MD, Yam C, Iwase T, Nelson B, Bassett R, Singareeka A, Whitman G, Karuturi M, Adrada B, Kizub D, Guirguis M, Buzdar A, Moseley T, Nwosu-Iheme A, Kapoor M, Sukumar J, Thomas P, Barcenas CH, Ibrahim N, Moscol G, Nasrazadani A, Ramirez D, Lee J, Woodward WA, Litton JK, Hunt K, Giordano S, Tripathy D, Valero V, Huo L, Rauch GM, Ueno N. Neosaci-io: Neoadjuvant Sacituzumab Govitecan (sg) + Pembrolizumab (pb) in Patients (pts) with Early-stage TNBC Experiencing Suboptimal Response to Keynote-522. Clin Cancer Res 32(4 Supplement), 2026. e-Pub 2026.
- Yam C, Radko A, Huo L, Akshara S, Ohanjanyan E, Yudina A, Kushnarev V, Hill H, Abouharb S, Adrada B, Arun B, Barcenas CH, Bisen A, Brewster A, Buzdar A, Gregor M, Damodaran S, Garber H, Guirguis M, Hassan A, Ibrahim N, Karuturi M, Kong E, Layman R, Moscol G, Mouabbi J, Murthy R, Nasrazadani A, Nelson B, Iheme AN, Oke O, Patel M, Pohlmann P, Ramirez D, Saleem S, Sukumar J, Sun J, Thomas P, Walters R, Wei P, Williams M, Wright M, Woodward W, Hunt K, Litton J, Valero V, Tripathy D, Rauch GM, Goldberg M, Korkut A. Circulating Immune Correlates of Pathological Response to Neoadjuvant Pembrolizumab plus Chemotherapy in High-Risk, Early-Stage Triple-Negative Breast Cancer. Clin Cancer Res 32(4 Supplement), 2026. e-Pub 2026.
- Yam C, Patel M, Sun J, Adrada BE, Raghavendra AS, Litton JK, Mouabbi JA, Iheme AN, Saleem S, Moscol G, Wright MD, Buzdar A, Murthy RK, Korkut A, Valero V, Tripathy D, Moseley TW, Wei P, Huo L, M Rauch AG. Early On-treatment (on-Rx) Tumor Volume Reduction (TVR) to Predict Response to the KEYNOTE-522 (KN-522) Regimen in Early Stage Triple Negative Breast Cancer (TNBC). J Clin Oncol 43(16 Supplemental:592), 2025. e-Pub 2025.
- Valero V, Mouabbi J, Alonzo H, Nwosu-Iheme A, Murthy R, Huang X, Qiao W, Patel M, Pohlmann PR, Rauch G, Checka C, Hunt K, Tripathy D, Meric-Bernstam F, Symmans F. 132P Neoadjuvant Zanidatamab for Stage I Node-Negative HER2-Positive Breast Cancer (BC). ESMO Open 8(1), 2023. e-Pub 2023.
- Patel A, Forat Lufti AA, Adaeze N, Markham MJ. An Interactive Multimodality Curriculum Teaching Medicine Residents about Oncologic Documentation and Billing. The Journal of Teaching and Learning Resources 8265, 2018. e-Pub 2018.
- Adaeze N, Cohen AJ. 3411 Impact of Hydroxyurea on Sickle Cell Patients in a Community Hospital. American Society of Hematology 126(23), 2015. e-Pub 2015.
- Sarina P, Nwosu Iheme A, Xu B, Fan Y, Yuan Y, Lavasani S, Mortimer J, Goel S, Tsimberidou A, Ibrahim N, Ahouharb S, Barcenas C, Karp D, Ahnert J. The Efficacy and Safety of Tinengotinib in Patients with Advanced or Metastatic HR+/HER2-Breast Cancer or TNBC. San Antonio Breast Cancer Symposium.
- Mouabbi J, Raghavendra AS, Wright M, Nwosu-Iheme A, Barcenas C. Validation of the Clinical Treatment Score Post-5 Years (CTS5) as a Predictor of Late Distant Recurrence (DR) for HR+ HER2-negative Invasive Lobular Carcinoma (ILC). San Antonio Breast Cancer Symposium.
- Nwosu Iheme A, Yam Clinton et al. Immune and ctDNA Correlates of Pathological Response to Neoadjuvant Pembrolizumab plus Chemotherapy in High-Risk, Early-Stage Triple Negative Breast Cancer. San Antonio Breast Cancer Symposium.
Patient Reviews
CV information above last modified August 06, 2026